Pfizer is licensing the technology behind OXECTA, called AVERSION, from Acura Pharmaceuticals.
OXECTA is indicated for the management of acute and chronic pain that is moderate to severe and where use of opioids is appropriate.
Read the Pfizer release on oxycodone.
Related Articles on Opioids for Pain Management:
Study: Prescription Drug-Related Harm Primarily Involved Opioids
Opioids Market Headed for Steeper Growth
Army Grants $5.6M to Research Sublingual Opioid for Pain
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.